Literature DB >> 20018353

ERG rearrangement metastasis patterns in locally advanced prostate cancer.

Sven Perner1, Maria A Svensson, Ruhella R Hossain, John R Day, Jack Groskopf, Ryan C Slaughter, Analee R Jarleborn, Matthias D Hofer, Rainer Kuefer, Francesca Demichelis, David S Rickman, Mark A Rubin.   

Abstract

OBJECTIVES: To interrogate multifocal prostate cancer (PCa) to determine its predilection for metastasis, using ERG rearrangement as marker of clonality. A hallmark of PCa is that distinct tumor foci may arise independently, which has important biological and clinical implications. Recent studies characterizing ERG-rearranged PCa possessing intrafocal homogeneity but interfocal heterogeneity support this hypothesis.
METHODS: We studied 26 patients who underwent prostatectomy and lymphadenectomy with at least 2 distinct PCa foci and 1 lymph node (LN) metastasis. Each focus was assessed for size, Gleason score, ERG rearrangement, and TMPRSS2-ERG transcript.
RESULTS: Fifteen of 26 cases exhibited interfocal homogeneity with regard to ERG rearrangement (ie, presence vs absence of ERG rearrangement). ERG rearrangement was present in all foci for 6 and absent in all foci for 9 cases. Two cases revealed interfocal heterogeneity with regard to rearrangement mechanism (ie, rearrangement through insertion or deletion). Eight of 26 cases revealed interfocal heterogeneity with regard to rearrangement status. In all cases with at least 1 ERG rearranged focus, we found the corresponding LN metastasis harboring an ERG rearrangement. Interestingly, in a subset of cases the rearrangement status in the LN did not correspond to size or Gleason score. All but 2 ERG rearranged foci had detectable TMPRSS2-ERG transcript levels.
CONCLUSIONS: When multifocal PCa demonstrates both ERG-positive and ERG-negative foci, the positive foci have a greater predilection for metastasis. Larger studies are needed to confirm the potential additional risk an ERG rearranged focus confers on the likelihood of disease progression. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ERG rearrangements; TMPRSS2-ERG; metastatic; prostate cancer

Mesh:

Substances:

Year:  2010        PMID: 20018353      PMCID: PMC2850965          DOI: 10.1016/j.urology.2009.10.010

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  30 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

3.  10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.

Authors:  M A Rubin; A Gerstein; K Reid; D G Bostwick; L Cheng; R Parsons; N Papadopoulos
Journal:  Hum Pathol       Date:  2000-04       Impact factor: 3.466

4.  Evidence of independent origin of multiple tumors from patients with prostate cancer.

Authors:  L Cheng; S Y Song; T G Pretlow; F W Abdul-Karim; H J Kung; D V Dawson; W S Park; Y W Moon; M L Tsai; W M Linehan; M R Emmert-Buck; L A Liotta; Z Zhuang
Journal:  J Natl Cancer Inst       Date:  1998-02-04       Impact factor: 13.506

5.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Prognostic factors in lymph node-positive prostate cancer.

Authors:  Matthias D Hofer; Rainer Kuefer; Wei Huang; Haojie Li; Tarek A Bismar; Sven Perner; Richard E Hautmann; Martin G Sanda; Juergen E Gschwend; Mark A Rubin
Journal:  Urology       Date:  2006-05       Impact factor: 2.649

7.  Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications.

Authors:  E T Ruijter; C A van de Kaa; J A Schalken; F M Debruyne; D J Ruiter
Journal:  J Pathol       Date:  1996-11       Impact factor: 7.996

8.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

9.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

10.  A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate.

Authors:  D R Greene; T M Wheeler; S Egawa; J K Dunn; P T Scardino
Journal:  J Urol       Date:  1991-10       Impact factor: 7.450

View more
  22 in total

1.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.

Authors:  Charles C Guo; Yan Wang; Li Xiao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Hum Pathol       Date:  2011-09-19       Impact factor: 3.466

2.  Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.

Authors:  Sumin Han; J Chad Brenner; Aaron Sabolch; Will Jackson; Corey Speers; Kari Wilder-Romans; Karen E Knudsen; Theodore S Lawrence; Arul M Chinnaiyan; Felix Y Feng
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

3.  Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Authors:  Yiwei Li; Dejuan Kong; Zhiwei Wang; Aamir Ahmad; Bin Bao; Subhash Padhye; Fazlul H Sarkar
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

4.  Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay.

Authors:  Alba Torres; Mohammed Alshalalfa; Scott A Tomlins; Nicholas Erho; Ewan A Gibb; Jijumon Chelliserry; Lony Lim; Lucia L C Lam; Sheila F Faraj; Stephania M Bezerra; Elai Davicioni; Kasra Yousefi; Ashley E Ross; George J Netto; Edward M Schaeffer; Tamara L Lotan
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

5.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

6.  Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease.

Authors:  Dolores Di Vizio; Matteo Morello; Andrew C Dudley; Peter W Schow; Rosalyn M Adam; Samantha Morley; David Mulholland; Mirja Rotinen; Martin H Hager; Luigi Insabato; Marsha A Moses; Francesca Demichelis; Michael P Lisanti; Hong Wu; Michael Klagsbrun; Neil A Bhowmick; Mark A Rubin; Crislyn D'Souza-Schorey; Michael R Freeman
Journal:  Am J Pathol       Date:  2012-09-27       Impact factor: 4.307

Review 7.  Recurrent gene fusions in prostate cancer: their clinical implications and uses.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

8.  Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood.

Authors:  Matthias Jost; John R Day; Ryan Slaughter; Theodore D Koreckij; Deanna Gonzales; Martin Kinnunen; Jack Groskopf; Harry G Rittenhouse; Robert L Vessella; Mark A Reynolds
Journal:  Mol Cancer       Date:  2010-07-02       Impact factor: 27.401

9.  TMPRSS2-ERG fusion transcripts expression in patients referred for prostate biopsy: combining detection in urine and needle rinse material.

Authors:  Nicolas Barry Delongchamps; Patrick Younes; Lydie Denjean; Marc Zerbib; Phuong-Nhi Bories
Journal:  World J Urol       Date:  2014-07-05       Impact factor: 4.226

10.  Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element.

Authors:  Liesbeth Clinckemalie; Lien Spans; Vanessa Dubois; Michaël Laurent; Christine Helsen; Steven Joniau; Frank Claessens
Journal:  Mol Endocrinol       Date:  2013-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.